Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06879002 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Apr 30, 2026 to Apr 30, 2027
    • Start date: Dec 30, 2025 to Dec 30, 2026
    • Study completion date: Dec 30, 2026 to Dec 30, 2027
    v5
  2. Start date: Jul 30, 2025 to Dec 30, 2025v4
  3. Start date: Apr 30, 2025 to Jul 30, 2025v3
  4. Study Status, Eligibilityv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
There are several approaches to the timing of antagonist administration in IVF/ICSI cycles. The primary goal is indeed to prevent premature ovulation, which could jeopardize the success of the cycle There is an emerging concept that suggests that the progesterone produced by the corpus luteum (formed after ovulation) might be sufficient to prevent further ovulation, obviating the need for antagonist or exogenous progesterone administration. This hypothesis relies on the natural regulatory mechanisms of the menstrual cycle to maintain a progesterone-dominated environment post-ovulation. We hypothesized that this approach would minimize treatment costs /burden without having an impact on the outcome.
Trial Details
NCT Number NCT06879002
Lead Sponsor ART Fertility Clinics LLC
Conditions
(from sponsor)		 Stimulation in the Ovary, IVF Outcome
Enrollment 252 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov